Clinical trials: Cephalalgia
Head and Neck Squamous Cell Carcinoma
Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients
This is a single-arm prospective clinical trial to determine the safety and feasibility of using transdermal buprenorphine in alleviation of radiation induced mucositis pain in head and neck cancer patients.
- Trial name
- NCT04752384
- Testing
- Buprenorphine, Tramadol, Oral Mucositis (OM) Pain App
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Postdural Puncture Headache
2 Dose Neuraxial Morphine for Prevention of PDPH
Neuraxial analgesia (most commonly continuous epidural or combined spinal epidural) is the most effective modality available for pain relief during labor.
- Trial name
- NCT02473276
- Testing
- Morphine, Sterile normal saline
- Where
- 4 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Columbia University
Migraine With or Without Aura, Migraine
Cooling to Alleviate Migraine #3
This is a prospective, double-blind, sham-controlled, randomized, decentralized trial. This study aims to assess the safety and efficacy of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home…
- Conditions
- Migraine With or Without Aura, Migraine, Migraine Headache
- Trial name
- CALM3 (NCT06874361)
- Testing
- Mi-Helper
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Mi-Helper, Inc.
Migraine Disorders
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- PROMISE 2 (NCT02974153)
- Testing
- ALD403 (Eptinezumab)
- Where
- 144 sites in United States, Belgium and 11 more
- Volunteers
- 1,121 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Acute Treatment Trial in Adult Subjects With Migraines
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
- Trial name
- NCT03872453
- Testing
- Zavegepant, Intranasal Aptar Pharma Unit Dose System
- Where
- 82 sites in United States
- Volunteers
- 2,154 people
- Sponsor
- Pfizer
Migraine Disorders, Stress
Mindfulness During COVID-19
The objective of this study is to provide remote mindfulness session(s) to help during the COVID-19 pandemic.
- Conditions
- Migraine Disorders, Stress, Anxiety
- Trial name
- NCT04319445
- Testing
- Mindfulness session(s)
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Headaches Associated With Subarachnoid Hemorrhage (SAH)
Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage
Headaches associated with subarachnoid hemorrhage (SAH) cause severe pain. Headache management is complex, requiring a balance between pain control and preservation of neurological assessment.
- Trial name
- NCT01851720
- Testing
- Low dose fentanyl PCA, Standard IV fentanyl bolus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Migraine
A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches.
- Trial name
- NCT00781456
- Testing
- 91-day Levonorgestrel Oral Contraceptive
- Where
- 22 sites in United States
- Volunteers
- 109 people
- Sponsor
- Duramed Research
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Migraine Disorders
A Multicenter Assessment of ALD403 in Chronic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- NCT02275117
- Testing
- ALD403
- Where
- 92 sites in United States, Australia and 2 more
- Volunteers
- 665 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Migraine
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
- Trial name
- NCT03670810
- Testing
- Lasmiditan
- Where
- 141 sites in United States, Austria and 15 more
- Volunteers
- 1,633 people
- Sponsor
- Eli Lilly and Company
Migraine
Dexamethasone for Migraine - Dose Comparison
Dexamethasone is an evidence-based treatment of acute migraine. This is a randomized comparison of two different doses of dexamethasone for acute migraine. All patients will also be treated with metoclopramide.
- Trial name
- NCT04112823
- Testing
- Dexamethasone 4mg, Dexamethasone 16mg
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Montefiore Medical Center
Migraine
A Study of LY3451838 in Participants With Migraine
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
- Trial name
- NCT04498910
- Testing
- LY3451838
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Migraine
An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine
This will be an exploratory observational trial of rescue acupuncture for the treatment of acute migraine in military beneficiaries to gain information to inform the power analysis of a larger, more definitive trial.
- Trial name
- NCT02764996
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mike O'Callaghan Military Hospital
Migraine
Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden
This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.
- Trial name
- NCT04461795
- Testing
- Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- David True
Migraine, Migraine Disorders
The Childhood and Adolescent Migraine Prevention Study
The purpose of this research study is to test two medicines for migraine prevention in children and adolescents.
- Conditions
- Migraine, Migraine Disorders, Headache
- Trial name
- CHAMP (NCT01581281)
- Testing
- Amitriptyline, Topiramate
- Where
- 35 sites in United States
- Volunteers
- 488 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Migraine
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine.
- Trial name
- NCT02665273
- Testing
- Greater occipital nerve block, Bupivacaine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Montefiore Medical Center
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.